KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neogenomics (NEO) EBT (2016 - 2025)

Historic EBT for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to -$26.4 million.

  • Neogenomics' EBT fell 4784.58% to -$26.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$114.0 million, marking a year-over-year decrease of 4278.56%. This contributed to the annual value of -$80.7 million for FY2024, which is 1691.3% up from last year.
  • As of Q3 2025, Neogenomics' EBT stood at -$26.4 million, which was down 4784.58% from -$45.8 million recorded in Q2 2025.
  • Neogenomics' EBT's 5-year high stood at $73.4 million during Q2 2021, with a 5-year trough of -$53.2 million in Q1 2022.
  • In the last 5 years, Neogenomics' EBT had a median value of -$25.7 million in 2025 and averaged -$23.7 million.
  • Within the past 5 years, the most significant YoY rise in Neogenomics' EBT was 50897.75% (2021), while the steepest drop was 114275.43% (2021).
  • Quarter analysis of 5 years shows Neogenomics' EBT stood at -$44.2 million in 2021, then soared by 42.26% to -$25.5 million in 2022, then surged by 40.11% to -$15.3 million in 2023, then dropped by 5.51% to -$16.1 million in 2024, then crashed by 63.62% to -$26.4 million in 2025.
  • Its EBT stands at -$26.4 million for Q3 2025, versus -$45.8 million for Q2 2025 and -$25.7 million for Q1 2025.